Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Janiczek-Dolphin

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The British Journal of Dermatology|June 4, 2010
Can sebum reduction predict acne outcome?N Janiczek-Dolphin, J Cook, D Thiboutot, et al.
Analytical Chemistry|January 7, 1998
Tandem-in-time mass spectrometry as a quantitative bioanalytical toolD T Rossi, K L Hoffman, N Janiczek-Dolphin, et al.
Journal of Thrombosis and Thrombolysis|December 21, 2000
The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosisT B McClanahan, G W Hicks, D P Ignasiak, et al.
European Journal of Pharmacology|December 13, 2001
The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosisT B McClanahan, G W Hicks, A L Morrison, et al.
Journal of Medicinal Chemistry|November 7, 2000
Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitorsD A Dudley, A M Bunker, L Chi, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The British Journal of Dermatology|June 4, 2010
Can sebum reduction predict acne outcome?N Janiczek-Dolphin, J Cook, D Thiboutot, et al.
Analytical Chemistry|January 7, 1998
Tandem-in-time mass spectrometry as a quantitative bioanalytical toolD T Rossi, K L Hoffman, N Janiczek-Dolphin, et al.
Journal of Thrombosis and Thrombolysis|December 21, 2000
The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosisT B McClanahan, G W Hicks, D P Ignasiak, et al.
European Journal of Pharmacology|December 13, 2001
The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosisT B McClanahan, G W Hicks, A L Morrison, et al.
Journal of Medicinal Chemistry|November 7, 2000
Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitorsD A Dudley, A M Bunker, L Chi, et al.
Pageof 1